BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He R, Finan B, Mayer JP, DiMarchi RD. Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules 2019;24:E1855. [PMID: 31091786 DOI: 10.3390/molecules24101855] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Parrasia S, Szabò I, Zoratti M, Biasutto L. Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges. Mol Pharm 2022. [PMID: 36174227 DOI: 10.1021/acs.molpharmaceut.2c00523] [Reference Citation Analysis]
2 Yang S, Banik N, Han B, Lee D, Park J. Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy. Pharmaceutics 2022;14:1378. [DOI: 10.3390/pharmaceutics14071378] [Reference Citation Analysis]
3 Chen CH, Liu YH, Eskandari A, Ghimire J, Lin LC, Fang ZS, Wimley WC, Ulmschneider JP, Suntharalingam K, Hu CJ, Ulmschneider MB. Integrated Design of a Membrane-Lytic Peptide-Based Intravenous Nanotherapeutic Suppresses Triple-Negative Breast Cancer. Adv Sci (Weinh) 2022;9:e2105506. [PMID: 35246961 DOI: 10.1002/advs.202105506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang L, Chen H, Wang F, Zhang X. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv 2022. [PMID: 35130795 DOI: 10.1080/17425247.2022.2039621] [Reference Citation Analysis]
5 Ma S, Ji J, Tong Y, Zhu Y, Dou J, Zhang X, Xu S, Zhu T, Xu X, You Q, Jiang Z. Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lupaescu A, Iavorschi M, Covasa M. The Use of Bioactive Compounds in Hyperglycemia- and Amyloid Fibrils-Induced Toxicity in Type 2 Diabetes and Alzheimer’s Disease. Pharmaceutics 2022;14:235. [DOI: 10.3390/pharmaceutics14020235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hart LR, Lebedenko CG, Mitchell SM, Daso RE, Banerjee IA. In Silico Studies of Tumor Targeted Peptide-Conjugated Natural Products for Targeting Over-Expressed Receptors in Breast Cancer Cells Using Molecular Docking, Molecular Dynamics and MMGBSA Calculations. Applied Sciences 2022;12:515. [DOI: 10.3390/app12010515] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Pryyma A, Matinkhoo K, Bu YJ, Merkens H, Zhang Z, Bénard F, Perrin DM. Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells. RSC Chem Biol 2022;3:69-78. [DOI: 10.1039/d1cb00036e] [Reference Citation Analysis]
9 Lindberg J, Nilvebrant J, Nygren PÅ, Lehmann F. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules 2021;26:6042. [PMID: 34641586 DOI: 10.3390/molecules26196042] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
10 He R, Mowery SA, Chabenne J, Finan B, Mayer JP, DiMarchi RD. A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs. Front Endocrinol (Lausanne) 2021;12:693958. [PMID: 34484114 DOI: 10.3389/fendo.2021.693958] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Shoari A, Tooyserkani R, Tahmasebi M, Löwik DWPM. Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade. Pharmaceutics 2021;13:1391. [PMID: 34575464 DOI: 10.3390/pharmaceutics13091391] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Park EY, Oh D, Park S, Kim W, Kim C. New contrast agents for photoacoustic imaging and theranostics: Recent 5-year overview on phthalocyanine/naphthalocyanine-based nanoparticles. APL Bioeng 2021;5:031510. [PMID: 34368604 DOI: 10.1063/5.0047660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Demeule M, Charfi C, Currie JC, Larocque A, Zgheib A, Kozelko S, Béliveau R, Marsolais C, Annabi B. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci 2021. [PMID: 34314556 DOI: 10.1111/cas.15086] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
14 Aghamiri S, Zandsalimi F, Raee P, Abdollahifar MA, Tan SC, Low TY, Najafi S, Ashrafizadeh M, Zarrabi A, Ghanbarian H, Bandehpour M. Antimicrobial peptides as potential therapeutics for breast cancer. Pharmacol Res 2021;171:105777. [PMID: 34298112 DOI: 10.1016/j.phrs.2021.105777] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Sato D, Wu Z, Fujita H, Lindsey J. Design, Synthesis, and Utility of Defined Molecular Scaffolds. Organics 2021;2:161-273. [DOI: 10.3390/org2030013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Liu C, Han Q, Liu H, Zhu C, Gui W, Yang X, Li W. Precise engineering of Gemcitabine prodrug cocktails into single polymeric nanoparticles delivery for metastatic thyroid cancer cells. Drug Deliv 2020;27:1063-72. [PMID: 32672077 DOI: 10.1080/10717544.2020.1790693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mendonça DA, Bakker M, Cruz-Oliveira C, Neves V, Jiménez MA, Defaus S, Cavaco M, Veiga AS, Cadima-Couto I, Castanho MARB, Andreu D, Todorovski T. Penetrating the Blood-Brain Barrier with New Peptide-Porphyrin Conjugates Having anti-HIV Activity. Bioconjug Chem 2021;32:1067-77. [PMID: 34033716 DOI: 10.1021/acs.bioconjchem.1c00123] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Battistini L, Bugatti K, Sartori A, Curti C, Zanardi F. RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances. Eur J Org Chem 2021;2021:2506-28. [DOI: 10.1002/ejoc.202100240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
19 Murabito A, Cnudde S, Hirsch E, Ghigo A. Potential therapeutic applications of AKAP disrupting peptides. Clin Sci (Lond) 2020;134:3259-82. [PMID: 33346357 DOI: 10.1042/CS20201244] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Kumar K, Suebsuwong C, Wang P, Garcia-Ocana A, Stewart AF, DeVita RJ. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes. J Med Chem 2021;64:2901-22. [PMID: 33682417 DOI: 10.1021/acs.jmedchem.0c02050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
21 Kulkarni N, Shinde SD, Jadhav GS, Adsare DR, Rao K, Kachhia M, Maingle M, Patil SP, Arya N, Sahu B. Peptide-Chitosan Engineered Scaffolds for Biomedical Applications. Bioconjug Chem 2021;32:448-65. [PMID: 33656319 DOI: 10.1021/acs.bioconjchem.1c00014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 Muñoz-Torrero D. The Cream of the Crop of the Medicinal Chemistry Section of Molecules-2019. Molecules 2021;26:1053. [PMID: 33671435 DOI: 10.3390/molecules26041053] [Reference Citation Analysis]
23 Balogh B, Ivánczi M, Nizami B, Beke-Somfai T, Mándity IM. ConjuPepDB: a database of peptide-drug conjugates. Nucleic Acids Res 2021;49:D1102-12. [PMID: 33125057 DOI: 10.1093/nar/gkaa950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Mironov AF, Ostroverkhov PV, Tikhonov SI, Pogorilyy VA, Kirin NS, Chudakova OO, Tsygankov AA, Grin MA. Amino acid derivatives of natural chlorins as a platform for the creation of targeted photosensitizers in oncology. Fine Chem Technol 2021;15:16-33. [DOI: 10.32362/2410-6593-2020-15-6-16-33] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Deonarain MP, Yahioglu G. Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy. Expert Opin Drug Discov 2021;16:613-24. [PMID: 33275475 DOI: 10.1080/17460441.2021.1858050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Patel TK, Adhikari N, Amin SA, Biswas S, Jha T, Ghosh B. Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery. New J Chem 2021;45:5291-321. [DOI: 10.1039/d0nj04134c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
27 Alas M, Saghaeidehkordi A, Kaur K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem 2021;64:216-32. [PMID: 33382619 DOI: 10.1021/acs.jmedchem.0c01530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
28 Ali H, Jabeen A, Maharjan R, Nadeem-Ul-Haque M, Aamra H, Nazir S, Khan S, Olleik H, Maresca M, Shaheen F. Furan-Conjugated Tripeptides as Potent Antitumor Drugs. Biomolecules 2020;10:E1684. [PMID: 33339257 DOI: 10.3390/biom10121684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Deonarain MP, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antib Ther 2020;3:237-45. [PMID: 33928231 DOI: 10.1093/abt/tbaa024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
30 Gamboa A, Schüßler N, Soto-bustamante E, Romero-hasler P, Meinel L, Morales JO. Delivery of ionizable hydrophilic drugs based on pharmaceutical formulation of ion pairs and ionic liquids. European Journal of Pharmaceutics and Biopharmaceutics 2020;156:203-18. [DOI: 10.1016/j.ejpb.2020.09.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Irais CM, María-de-la-Luz SG, Dealmy DG, Agustina RM, Nidia CH, Mario-Alberto RG, Luis-Benjamín SG, María-Del-Carmen VM, David PE. Plant Phenolics as Pathogen-Carrier Immunogenicity Modulator Haptens. Curr Pharm Biotechnol 2020;21:897-905. [PMID: 31965941 DOI: 10.2174/1389201021666200121130313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wang J, Tripathy N, Chung EJ. Targeting and therapeutic peptide-based strategies for polycystic kidney disease. Adv Drug Deliv Rev 2020;161-162:176-89. [PMID: 32866560 DOI: 10.1016/j.addr.2020.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kumari S, Carmona AV, Tiwari AK, Trippier PC. Amide Bond Bioisosteres: Strategies, Synthesis, and Successes. J Med Chem 2020;63:12290-358. [PMID: 32686940 DOI: 10.1021/acs.jmedchem.0c00530] [Cited by in Crossref: 34] [Cited by in F6Publishing: 90] [Article Influence: 17.0] [Reference Citation Analysis]
34 Ma Y, Mou Q, Yan D, Zhu X. Engineering small molecule nanodrugs to overcome barriers for cancer therapy. View 2020;1:20200062. [DOI: 10.1002/viw.20200062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
35 Gupta S, Singh I, Sharma AK, Kumar P. Ultrashort Peptide Self-Assembly: Front-Runners to Transport Drug and Gene Cargos. Front Bioeng Biotechnol 2020;8:504. [PMID: 32548101 DOI: 10.3389/fbioe.2020.00504] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
36 Bondar K, Bokan M, Gellerman G, Patsenker LD. Water-soluble 4-hydroxystyryl and 4-hydroxyphenyl-butadienyls dyes with switchable fluorescence. Dyes and Pigments 2020;172:107801. [DOI: 10.1016/j.dyepig.2019.107801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Patsenker L, Gellerman G. Fluorescent Reporters for Drug Delivery Monitoring. Isr J Chem 2020;60:504-18. [DOI: 10.1002/ijch.201900137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
38 Passioura T. The Road Ahead for the Development of Macrocyclic Peptide Ligands. Biochemistry 2020;59:139-45. [PMID: 31592645 DOI: 10.1021/acs.biochem.9b00802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
39 Ebaston TM, Rozovsky A, Zaporozhets A, Bazylevich A, Tuchinsky H, Marks V, Gellerman G, Patsenker LD. Peptide‐Driven Targeted Drug‐Delivery System Comprising Turn‐On Near‐Infrared Fluorescent Xanthene–Cyanine Reporter for Real‐Time Monitoring of Drug Release. ChemMedChem 2019;14:1727-34. [DOI: 10.1002/cmdc.201900464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
40 Petersen J, Strømgaard K, Frølund B, Clemmensen C. Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. Drugs 2019;79:1187-97. [DOI: 10.1007/s40265-019-01153-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
41 Rozovsky A, Ebaston TM, Zaporozhets A, Bazylevich A, Tuchinsky H, Patsenker L, Gellerman G. Theranostic system for ratiometric fluorescence monitoring of peptide-guided targeted drug delivery. RSC Adv 2019;9:32656-64. [DOI: 10.1039/c9ra06334j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]